Neoadjuvant therapy (NAT) is the standard initial treatment for Triple Negative and Her2+ breast cancers. The tumour response to NAT diverges widely due to the influence of several individual factors, including microbiota, that have a crucial role in immune response and in conditioning molecular pathways. Thus, a systematic and integrated stratification of the patients at the onset of the disease, together with the evaluation of the common decision-making criteria, will help to recognise responders and improve patient care and quality of life. PORTRAIT aims to create a multidimensional ID of responders and non-responders to NAT integrating host characteristics and clinical data with tissue and distal microbiota characteristics (gut and skin microbiota) to detect the individual panel of determinants affecting the therapeutic outcome by a multiomic approach. It also aims to create a non-invasive predictive tool based on volatilomics and test personalised therapy approaches in 3D models.